Mitochondria in neurodegenerative apoptosis: An opportunity for therapy?

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Tatton, William G ^a   Chalmers Redman, Ruth M E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; APOPTOSIS; BRAIN MITOCHONDRION; CHROMATIN CONDENSATION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DNA DEGRADATION; HUMAN; MEMBRANE TRANSPORT; MITOCHONDRIAL MEMBRANE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON TRANSPORT;

EID: 0031669690     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440720     Document Type: Conference Paper

References (82)

1. Tatton WG, Chalmers-Redman RME, Ju WYH, Wadia J, Tatton NA. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm 1997;49:245-268
2. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998; 44(Suppl 1):S142-S148 (this issue)
3. Johnson J, Oppenheim R. Neurotrophins. Keeping track of changing neurotrophic theory. Curr Biol 1994;4:662-665
4. Mitchell IJ, Lawson S, Moser B, et al. Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience 1994;63:1-5
5. Estus S, Tucker HM, van Rooyen C, et al. Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J Neurosci 1997; 17:7736-7745
6. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport 1993;4:523-526
7. Guo Q, Sopher BL, Furukawa K, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci 1997;17:4212-4222
8. Janicki S, Monteiro MJ. Increased apoptosis arising from increased expression of the Alzheimer's disease-associated presenilin-2 mutation (N141I). J Cell Biol 1997;139:485-495
9. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997;77:1037-1048
10. Gobe GC. Apoptosis in brain and gut tissue of mice fed a seed preparation of the cycad Lepidozamia peroffskyana. Biochem Biophys Res Commun 1994;205:327-333
11. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994;63: 1987-1990
12. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area and the effect of postmortem delay. J Neurosci 1996;16:1710-1719
13. Johnson GVW, Cox TM, Lockhart JP, Zinnerman MD, Miller ML, Powers RE. Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 1997;751:323-329
14. Su JH, Deng GM, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 1997l56:86-93
15. Arendt T, Rodel L, Gartner U, Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 1996;7:3047-3049
16. Nagy Z, Esiri MM, Cato AM, Smith AD. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl) 1997;94:6-15
17. MacGibbon GA, Lawlor PA, Sirimanne ES, et al. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res 1997;750:223-234
18. Nishimura T, Akiyama H, Yonehara S, et al. Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res 1995;695:137-145
19. Kitamura Y, Kosaka T, Shimohama S, Nomura Y, Taniguchi T. Possible involvement of rapamycin-sensitive pathway in Bcl-2 expression in human neuroblastoma SH-SY5Y cells. Jpn J Pharmacol 1997;75:195-198
20. Vyas S, Javoy Agid F, Herrero MT, et al. Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders. J Neurochem 1997;69:223-231
21. Mogi M, Harada M, Kondo T, et al. Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 1996; 215:137-139
22. Sherratt HSA. Mitochondria: structure and function. Rev Neurol (Paris) 1991;147:417-430
23. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:44-51
24. Scorrano L, Petronilli V, Bernardi P. On the voltage dependence of the mitochondrial permeability transition pore - a critical appraisal. J Biol Chem 1997;272:12295-12299
25. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore: a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerget Biomembr 1994;26:509-517
26. Scorrano L, Nicolli A, Basso E, Petronilli V, Bernardi P. Two modes of activation of the permeability transition pore: the role of mitochondrial cyclophilin. Mol Cell Biochem 1997;174: 181-184
27. Chernyak BV, Bernardi P. The mitochondrial permeability pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur J Biochem 1996;238:623-630
28. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta [Rev Biomembr] 1995;1241:139-176
29. Hirsch T, Marzo I, Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep 1997;17: 67-76
30. Susin SA, Zamzami N, Kroemer G. The cell biology of apoptosis: evidence for the implicarion of mitochondria. Apoptosis 1996;1:231-242
31. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition interfere with the disruption of mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996;384:53-57
32. Wadia JS, Chalmers-Redman RME, Ju WJH, Carlile GW, Phillips JL, Tatton WG. Mitochondrial membrane potential and nuclear changes in apoptosis caused by trophic withdrawal: time course and modification by (-)-deprenyl. J Neurosci 1998;18:932-947
33. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluroimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,31-tetraethylbenzi- midazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993;197:40-45
34. Smiley ST, Reers M, Mottola-Hartshorn C, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991;88:3671-3675
35. Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994;79: 353-364
36. Susin SA, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996;184:1331-1341
37. Carayon P, Portier M, Dussossoy D, et al. Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood 1996;87: 3170-3178
38. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:1155-1160
39. Marchetti P, Hirsch T, Zamzami N, et al. Mitochondrial permeability Transition triggers lymphocyte apoptosis. J Immunol 1996;157:4830-4836
40. Liu XS, Kim CN, Yang J, Jemmerson R, Wang XD. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-157
41. Yang J, Liu XS, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochtome c from mitochondria blocked. Science 1997;275:1129-1132
42. Kluck RM, Bossy Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136
43. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC(6)(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77-82
44. Kantrow SP, Piantadosi CA. Release of cytochrome c from liver mitochondria during permeability transition. Biochem Biophys Res Commun 1997;232:669-671
45. Chauchan D, Pandey P, Ogata A, et al. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chem 1997;272:29995-29997
46. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ, Fritz LC. Cell specific induction of apoptosis by microinjection of cytochrome c. J Biol Chem 1997;272:30299-30305
47. Kharbanda S, Pandey P, Schofield L, et al. Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 1997;94: 6939-6942
48. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132
49. Oppenheim RW, Prevette D, Tytell M, Homma S. Naturally occurring and induced neuronal death in the chick embryo in vivo requires protein and RNA synthesis: evidence for the role of cell death genes. Dev Biol 1990;138:104-113
50. Eastman A. Apoptosis: a product of programmed and unprogrammed cell death. Toxicol Appl Pharmacol 1993;121:160-164
51. Rukenstein A, Rydel RE, Greene LA. Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms. J Neurosci 1991;11: 2552-2563
52. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575
53. Mesner PW, Epting CL, Hegarty JL, Green SH. A timetable of events during programmed cell death induced by trophic factor withdrawal from neuronal PC12 cells. J Neurosci 1995;15: 7357-7366
54. Bellamy CO. p53 and apoptosis. Br Med Bull 1997;53:522-538
55. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389(6648): 300-305
56. Nieminen AL, Byrne AM, Herman B, Lemasters JJ. Mitochondrial permeability transition in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species. Am J Physiol 1997;41:C1286-1294
57. Caelles C, Heimberg A, Kann M. p53-dependent apoptosis in the absence of p53-target genes. Nature 1994;370:220-223
58. Wagner AJ, Kokontis JM, Hay N. MYC-mediated apoptosis requires wild type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21. Genes Dev 1994; 8:2817-2830
59. Haupt Y, Barak Y, Oren M. Cell type specific inhibition of p53 mediated apoptosis by mdm2. EMBO J 1996;15:1598-1606
60. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD. Complex 1, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881
61. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992;115: 333-342
62. Parker WD, Boyson SJ, Parks JK. Abnormalities of electron transport in Parkinson's disease. Ann Neurol 1989;50:719-723
63. Reichmann H, Naumann M, Hauck S, Janetzky B. Respiratory chain and mitochondrial deoxyribonucleic acid in blood cells from patients with focal and generalized dystonia. Mov Disord 1994;9:597-600
64. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827
65. Yoshino H, Nakagawa Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm [Park Dis Dement Sect] 1992;4:27-34
66. Benecke R, Strumper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993;116:1451-1463
67. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32:782-788
68. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722
69. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-671
70. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455
71. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145
72. Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 1991;30:563-571
73. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994; 35:204-210
74. Mytilineou C, Werner P, Molinari S, DiRocco A, Cohen G, Yahr MD. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neurol Transm [Park Dis Dement Sect] 1994;8:223-228
75. Brown MD, Shoffner JM, Kim YL, et al. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Am J Med Genet 1996;61:283-289
76. Lucking CB, Kosel S, Mehraein P, Graeber MB. Absence of the mitochondrial A7237T mutation in Parkinson's disease. Biochem Biophys Res Commun 1995;211:700-704
77. Mizuno Y, Ikebe S, Hattori N, et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1995;1271:265-274
78. Schapira AH. Nuclear and mitochondrial genetics in Parkinson's disease. J Med Genet 1995;32:411-414
79. Davey GP, Clark JB. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J Neurochem 1996;66:1617-1624
80. Ghelli A, Benelli B, Esposti MD. Measurement of the membrane potential generated by complex I in submitochondrial particles. J Biochem 1997;121:746-755
81. Tatton WG, Ju WJH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Youdim M, Jenner P, eds. Neuroprotection and neurodegeneration. New York: Academic Press, 1996:209-229
82. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47:S171-183